Article Sidebar

PDF
Date Published: 20/07/2021
Abstract Views: 341
Views PDF: 158
DOI: https://doi.org/10.51298/vmj.v501i1.420
Issue
Vol. 501 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Thái Hòa, N. . (2021). RESULTS OF ANALYSIS SUBGROUPS OF NON-SMALL CELL LUNG CANCER TREATED WITH VINORELBINE METRONOMIC. Vietnam Medical Journal, 501(1). https://doi.org/10.51298/vmj.v501i1.420

RESULTS OF ANALYSIS SUBGROUPS OF NON-SMALL CELL LUNG CANCER TREATED WITH VINORELBINE METRONOMIC

Nguyễn Thị Thái Hòa

Main Article Content

Abstract

Objective: To evaluate treatment result of subgroups of Advanced – stage Non – small cell Lung cancer treated by Vinorelbine Metronomic. Patients: Advanced - stage Non - small cell Lung cancer patients progressed after first - line chemotherapy. Method: Retrospective study. Patients were given Vinorelbine 50mg twice or 3 times a week. Results and Conclusion: Treatment results did not differ between age groups. Results were higher in patients on second - line treatment compared with treatment from third line; ECOG 0,1 vs ECOG> 1.

Article Details

Keywords

Vinorelbine metronomic, advanced – stage, non – small cell lung cancer

References

1. Antonio G, Nicola S, Antonnela L, et al. (2015) “Metronomic chemotherapy from rationale to clinical studies: a dream or reality”. Clinical reviews in Oncology/ Hematology 95 (2015) 46-61.
2. Magdalena K-W, Maciej K. (2016) “Metronomic chemotherapy in non - small - cell lung cancer - current status” Oncol Clin Pract 2016; 12, 2: 37-42.
3. C. Bilir ,S. Durak B, Kızılkaya, et al. (2017) “Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status”. Curr Oncol. 2017 June;24(3):199-204.
4. MichelaD’Ascanio, Aldo Pezzuto, Chiara Fiorentino (2018), “Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer”. Hindawi BioMed Research International Volume 2018, Article ID 6278403, 6 pages https:// doi.org/10.1155/2018/6278403.
5. Andrea Camerini, et al, (2015) “ Metronomic oral vinorelbin as first –line treatment in elderly patients with advanced non - small cell lung cancer: result of a phase II trial (MOVE trial)”. BMC Cancer 2015, 15-359.
6. Camerini , Valsuani, Mazzoni, Siclari, (2010) “Phase II trials of single- agent oral vinorelbine in elderly (≥ 70 years) patients with advanced non small cell lung cancer and poor performance status”. Ann Oncol (2010) 21(6): 1290-1295.
7. Emmanouil Kontopodis, Dora Hatzidak, Ioannis Varthalitis, et al (2013). “A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group” Journal of Chemotherapy 2013 VOL. 25 NO. 1, 49- 55.